NV4 Stock Overview
A clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Cellectar Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.55 |
| 52 Week High | US$3.88 |
| 52 Week Low | US$1.51 |
| Beta | 1.01 |
| 11 Month Change | -17.55% |
| 3 Month Change | -17.99% |
| 1 Year Change | -20.92% |
| 33 Year Change | -75.59% |
| 5 Year Change | -90.19% |
| Change since IPO | -99.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| NV4 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -23.3% | 0.8% | -0.4% |
| 1Y | -20.9% | -16.7% | 7.1% |
Return vs Industry: NV4 underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: NV4 underperformed the German Market which returned 7.8% over the past year.
Price Volatility
| NV4 volatility | |
|---|---|
| NV4 Average Weekly Movement | 7.7% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: NV4's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: NV4's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 20 | Jim Caruso | www.cellectar.com |
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom’s macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin’s lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors.
Cellectar Biosciences, Inc. Fundamentals Summary
| NV4 fundamental statistics | |
|---|---|
| Market cap | €54.76m |
| Earnings (TTM) | -€47.54m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.1x
P/E RatioIs NV4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NV4 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$50.11m |
| Earnings | -US$50.11m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.40 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NV4 perform over the long term?
See historical performance and comparison